Premium
Does indomethacin for closure of patent ductus arteriosus affect cerebral function?
Author(s) -
Flisberg A,
Kjellmer I,
Löfhede J,
Löfgren N,
RosaZurera M,
Lindecrantz K,
Thordstein M
Publication year - 2010
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2010.01857.x
Subject(s) - medicine , ductus arteriosus , affect (linguistics) , closure (psychology) , cardiology , communication , law , sociology , political science
Objective: To study whether indomethacin used in conventional dose for closure of patent ductus arteriosus affects cerebral function measured by Electroencephalograms (EEG) evaluated by quantitative measures. Study design: Seven premature neonates with haemodynamically significant persistent ductus arteriosus were recruited. EEG were recorded before, during and after an intravenous infusion of 0.2 mg/kg indomethacin over 10 min. The EEG was analysed by two methods with different degrees of complexity for the amount of low‐activity periods (LAP, “suppressions”) as an indicator of affection of cerebral function. Results: Neither of the two methods identified any change in the amount of LAPs in the EEG as compared to before the indomethacin infusion. Conclusion: Indomethacin in conventional dose for closure of patent ductus arteriosus does not affect cerebral function as evaluated by quantitative EEG.